Anzeige
Mehr »
Login
Freitag, 24.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
InnoCan Pharma: Jetzt in die Doppel-Chance investieren?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DNZ4 | ISIN: US75915K3095 | Ticker-Symbol: 7RG0
Tradegate
23.05.24
15:45 Uhr
1,730 Euro
-0,050
-2,81 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
REGULUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
REGULUS THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,7401,82023.05.
1,7501,81023.05.

Aktuelle News zur REGULUS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiBio-Techne Corporation: Bio-Techne Highlights Recently Announced Top-line Biomarker Data From Partner, Regulus Therapeutics, Using The Company's Proprietary Technology38MINNEAPOLIS, May 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines...
► Artikel lesen
MoRegulus Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans1
17.05.Regulus Therapeutics Inc. - 8-K, Current Report1
16.05.Regulus Therapeutics Names New Chief Medical Officer1
16.05.Regulus Therapeutics names Rekha Garg as chief medical officer2
16.05.Regulus Therapeutics Inc.: Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer65SAN DIEGO, May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs...
► Artikel lesen
09.05.Regulus Therapeutics Inc. - 10-Q, Quarterly Report1
09.05.Regulus Therapeutics Inc. - 8-K, Current Report1
09.05.Regulus Therapeutics Inc.: Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates43Initiated the fourth cohort of patients in the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Topline data...
► Artikel lesen
06.05.Regulus Therapeutics Inc.: Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)60SAN DIEGO, May 6, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs...
► Artikel lesen
09.04.Regulus files to sell 62.5M shares of common stock for holders4
21.03.Regulus Therapeutics Inc reports results for the quarter ended in December - Earnings Summary4
21.03.Regulus Therapeutics GAAP EPS of -$0.40 in-line1
21.03.Regulus Therapeutics Inc. - 10-K, Annual Report1
21.03.Regulus Therapeutics Inc.: Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates242Positive topline data from the second cohort of patients in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Oversubscribed...
► Artikel lesen
14.03.Regulus Therapeutics Inc. - 8-K, Current Report2
14.03.Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More5
13.03.Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study7
13.03.Wells Fargo lifts Regulus Therapeutics stock PT to $3 on Cohort 2 data4
12.03.Regulus Therapeutics doubles as kidney disease therapy shows promise in trial3
Seite:  Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1